Experimental cocktail aims to shrink untreatable esophageal tumors
NCT ID NCT07086469
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether adding the drug surufatinib to standard chemo-immunotherapy and radiation can help people with advanced esophageal cancer that cannot be removed by surgery. The study will enroll 69 participants in China and track how long they live without the cancer getting worse. The goal is to see if this combination is safe and effective enough to improve outcomes for this hard-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- surufatinib (an anti-cancer drug) combined with chemotherapy (albumin-bound paclitaxel, cisplatin), immunotherapy (toripalimab), and radiation
- What this could lead to
- If successful, this combination could shrink or control advanced esophageal tumors that cannot be surgically removed, potentially improving survival without the need for surgery.
- What could go wrong
- This is an early phase II trial with only 69 participants, so results may not apply to all patients. The drug combination may cause significant side effects, and it is not yet known if it works better than standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMORADIOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- AI biomarker may reveal who responds to esophageal cancer immunotherapy
- Could a common heart drug boost cancer treatment? a trial puts propranolol to the test
- Can a single Protein's mutations predict esophageal cancer outcomes?